Gyre Therapeutics, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2017 | $-4.3M | $-4.3M | $3.0K | $120.0K |
| Jun 2017 | $-4.4M | $-4.4M | $0 | — |
| Sep 2017 | $-4.9M | $-4.9M | $0 | — |
| Mar 2018 | $-5.1M | $-5.3M | $198.0K | $606.0K |
| Jun 2018 | $-7.4M | $-7.4M | $3.0K | — |
| Sep 2018 | $-7.0M | $-7.0M | $0 | — |
| Mar 2019 | $-15.0M | $-15.0M | $15.0K | $829.0K |
| Jun 2019 | $-11.5M | $-11.5M | $49.0K | — |
| Sep 2019 | $-9.1M | $-9.1M | $1.0K | — |
| Mar 2020 | $-4.8M | $-4.8M | $17.0K | $805.0K |
| Jun 2020 | $-15.1M | $-15.2M | $16.0K | — |
| Sep 2020 | $-13.0M | $-13.2M | $195.0K | — |
| Mar 2021 | $-24.4M | $-24.4M | — | $1.0M |
| Jun 2021 | $-20.1M | $-20.1M | — | — |
| Sep 2021 | $-21.6M | $-21.6M | — | — |
| Mar 2022 | $-12.1M | $-12.1M | — | $515.0K |
| Jun 2022 | $-12.3M | $-12.3M | — | — |
| Sep 2022 | $-7.3M | $-7.3M | — | — |
| Mar 2023 | $10.4M | $8.7M | $1.7M | $210.0K |
| Jun 2023 | $4.5M | $2.1M | $2.5M | — |
| Sep 2023 | $7.6M | $5.6M | $2.0M | — |
| Mar 2024 | $2.9M | $2.7M | $231.0K | $11.0K |
| Jun 2024 | $-5.5M | $-6.9M | $1.5M | — |
| Sep 2024 | $1.7M | $1.0M | $693.0K | — |
| Mar 2025 | $-129.0K | $-251.0K | $122.0K | $507.0K |
| Jun 2025 | $-7.5M | $-7.8M | $335.0K | — |
| Sep 2025 | $14.2M | $13.6M | $589.0K | — |
| Mar 2026 | $3.2M | $3.0M | $178.0K | $2.6M |
| Jun 2026 | $-16.7M | $-17.0M | $262.0K | — |